This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A third look at the clinical landscape for prevention of major cardiovascular events, including an in depth discussion about the phase 2 data of Milvexian, a factor XIa inhibitor
Ticker(s): BMY, JNJWho's the expert?
Institution: New York Presbyterian Medical Center
- Vascular neurologist and an assistant professor of clinical neurology at Weill Cornell Medicine
- Clinical interest in management and prevention of stroke, intracerebral hemorrhage, and stroke in young adults
- Graduated from New York Institute of Technology College of Osteopathic Medicine, Residency in neurology at NorthWell Health, Fellowship in vascular neurology and stroke at Montefiore Medical Center.
- Manages over 100 patients on anticoagulation medications
Interview GoalTo discuss the clinical landscape and prescribing habits for major cardiovascular events with a cardiologist. Also, taking a look at Bristol Myers and JNJ's newest phase 2 results of Milvexian, a factor XIa inhibitor for the prevention of recurrent ischemic stroke.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
